Replies to post #6672 on Arbutus Biopharma Corporation (ABUS)

[DewDiligence]

Lowering HBsAg is the easy part. The question is whether patients who stop treatment will relapse and need to go back on drug; if these patients relapse, then the triple-drug regimen of Imdusiran (AB-729), VTP-300, and a nucleoside is no better than a nucleoside alone.

In other words, it’s too soon to say whether the 3-drug regimen discussed in the ABUS/BRNS* joint PR has any merit.

*f/k/a VACC.